FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA - PubMe
6 hours ago
- #CAR-T Therapy
- #Multiple Myeloma
- #Real-World Evidence
- Study evaluates real-world outcomes of ciltacabtagene autoleucel (cilta-cel) in US patients with relapsed/refractory multiple myeloma after ≥4 prior lines of therapy.
- Among 242 patients, 75.2% received bridging therapy (BT), and those with BT had higher comorbidity and frailty burden compared to those without.
- At 18 months post-infusion, the estimated treatment-free interval (TFI) was 80.3% and overall survival (OS) was 93.4%, with median TFI and OS not reached.
- Patients receiving BT showed trends toward better outcomes, with hazard ratios of 0.76 for TFI and 0.48 for OS, though confidence intervals were wide and included 1.
- Findings align with pivotal trials, supporting cilta-cel's effectiveness in clinical practice and the use of bridging therapy.